LEXINGTON, Mass., May 6,
2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of innovative
therapeutics for the treatment of cancer, today announced that the
Phase 1 study of CA-170 has reached its target enrollment of
mesothelioma patients. The company began enrolling and dosing
patients in this study in January.
"We are pleased to announce we have completed enrollment of the
CA-170 study three months ahead of schedule. Last November,
we outlined the reorganization of company resources to strengthen
our focus on clinical execution. Today's announcement is a direct
result of those efforts," said James
Dentzer, President & CEO of Curis. "If the data from
this phase of the trial, which is expected in the 2nd half of this
year, is positive, we expect to initiate an expansion of the
study."
CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes
could provide benefit in tumors with high levels of VISTA expression. Over 90% of mesothelioma
cancers express high levels of VISTA.
CA-170 is the only anti-VISTA
therapeutic currently being studied in a clinical trial. CA-170 has
demonstrated favorable safety and tolerability, as well as
preliminary anti-tumor activity in patients across multiple tumor
types. The Phase 1 study is the first clinical trial of
CA-170 to specifically target a patient population characterized by
high levels of VISTA
expression.
About the Study
The Phase 1, open-label, dose
escalation and dose expansion trial evaluating the safety,
pharmacokinetics, pharmacodynamics, and clinical effects of orally
administered CA-170 in patients with advanced tumors and lymphomas.
The dedicated mesothelioma cohort will evaluate CA-170 at two dose
levels.
About VISTA
VISTA (V-domain Ig-containing Suppressor of T
cell Activation) is an independent, inhibitory T cell checkpoint
protein that is expressed on both immune cells and tumor cells.
VISTA has been identified as a
potential resistance mechanism to treatment with anti-PD1
antibodies in melanoma and anti-CTLA4 antibodies in prostate
cancer. Recent literature indicates that high levels of
VISTA expression have been found
on various tumors, including mesothelioma, ovarian cancer,
endometrial cancer, triple negative breast cancer, gastric cancer,
and non-small cell lung cancer.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer, including
fimepinostat, which is being investigated in clinical studies in
patients with DLBCL and solid tumors. Curis is also engaged in a
collaboration with Aurigene to develop first-in-class therapeutics
in immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the
TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor,
CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial
in patients with advanced solid tumors, lymphomas, and mesothelioma
and in a Phase 2 trial in India
conducted by Aurigene. CA-4948 is currently undergoing testing in a
Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also
party to a collaboration with Genentech, a member of the Roche
Group, under which Genentech and Roche are commercializing
Erivedge® for the treatment of advanced basal cell carcinoma. For
more information, visit Curis's website at www.curis.com.
View original
content:http://www.prnewswire.com/news-releases/curis-completes-mesothelioma-enrollment-in-ca-170-study-300844017.html
SOURCE Curis, Inc.